We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Diagnostic Efficacy of Immunomarkers in Fungal Bloodstream Infection

By LabMedica International staff writers
Posted on 05 Feb 2020
Fungemia is the presence of fungi or yeasts in the blood and is a life‐threatening condition with the global mortality rate surging more than fivefold in the past decade. More...
It has been reported that the outcome depends on early and targeted treatment; thus, prompt diagnosis is essential at the early stage of infection.

Currently, early diagnosis of fungemia remains a complicated issue. Although blood culture remains the reference method for the detection of fungemia, this method takes 3‐5 days to generate positive results and also suffers from low sensitivity, which could not meet the requirement of early diagnosis and clinical guidance for fungemia.

Clinical Laboratory scientists at the Chinese PLA General Hospital (Beijing, China) included in their study 41 patients with fungemia who were compared with 57 patients with negative blood culture results. Blood samples for culture were taken from the patients for two to three times and inoculated using BACTEC PLUS Aerobic/F (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) blood culture bottles. The isolations from blood culture were identified to species with VETIK YBC card (bioMérieux, Marcy-l'Étoile, France) and bioMérieux MALDI‐TOF‐MS.

The serum samples were analyzed using the xMAP Bead Array Platform (Luminex Corporation, Austin, TX, USA). A combination of 14 cytokines and chemokines was quantified using the reagents of selected ones from Human Cytokine 30‐Plex Panel Kit (Merck-Millipore, Burlington, MA, USA). Evaluated cytokines included the following: IL‐1β, ‐2, ‐3, ‐4, ‐6, ‐8, 10, 17, 12p70, INF‐γ, TNF‐α, G‐CSF, RANTES, and MIP‐1β. C-reactive protein (CRP) was measured using nephelometric method (Siemens BNII, Cardiophase, Erlangen, Germany), and procalcitonin (PCT) was measured by cobas 800 (Roche, Basel Switzerland) based on electrochemical luminescence technology.

The scientists reported that C‐reactive protein and procalcitonin were significantly higher compared with those in negative control group, while white blood cell, percentage of neutrophil, percentage of lymphocyte, and ratio of neutrophil and lymphocyte did not differentiate between two groups. Serum levels of IFN‐γ, TNF‐α, MIP‐1β, IL‐6, IL‐8, IL‐10, IL‐12p70, and IL‐17 were significantly higher in patients with fungemia compared with the control group. Combination of MIP‐1β and IL‐17 could improve the AUC, sensitivity, and specificity for the diagnosis of fungemia.

The authors concluded that they had found eight serum cytokines/chemokines that significantly increased in the fungemia group when compared with the culture‐negative control group. Among them, MIP‐1β and IL‐17 might be given more attention during the diagnosis of fungemia. The study was published on January 23, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Chinese PLA General Hospital
Becton, Dickinson and Company
Merck-Millipore
bioMérieux
Luminex Corporation
Siemens
Roche



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.